98%
921
2 minutes
20
DNA-encoded chemical libraries (DELs) consist of large chemical compound collections individually linked to DNA barcodes, facilitating pooled construction and screening. However, screening campaigns often fail if the molecular arrangement of the building blocks is not conducive to an efficient interaction with a protein target. Here we postulated that the use of rigid, compact and stereo-defined central scaffolds for DEL synthesis may facilitate the discovery of very specific ligands capable of discriminating between closely related protein targets. We synthesized a DEL comprising 3,735,936 members, featuring the four stereoisomers of 4-aminopyrrolidine-2-carboxylic acid as central scaffolds. The library was screened in comparative selections against pharmaceutically relevant targets and their closely related protein isoforms. Hit validation results revealed a strong impact of stereochemistry, with large affinity differences between stereoisomers. We identified potent isozyme-selective ligands against multiple protein targets. Some of these hits, specific to tumour-associated antigens, demonstrated tumour-selective targeting in vitro and in vivo. Collectively, constructing DELs with stereo-defined elements contributed to high library productivity and ligand selectivity.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1038/s41557-023-01257-3 | DOI Listing |
Chem Pharm Bull (Tokyo)
August 2025
Graduate School of Pharmaceutical Sciences, The University of Osaka.
Recently, oligonucleotide-based drug discovery has attracted considerable amounts of attention. As oligonucleotide therapeutics have evolved into practical use, research into the development of functional artificial nucleic acids has been vigorously conducted worldwide. However, the synthesis of artificial nucleic acids generally requires long sequences from starting materials; hence, structurally optimizing oligonucleotide therapeutics is extremely difficult.
View Article and Find Full Text PDFMedComm (2020)
September 2025
DP Technology Beijing China.
RNA-targeting small molecules represent a transformative frontier in drug discovery, offering novel therapeutic avenues for diseases traditionally deemed undruggable. This review explores the latest advancements in the development of RNA-binding small molecules, focusing on the current obstacles and promising avenues for future research. We highlight innovations in RNA structure determination, including X-ray crystallography, nuclear magnetic resonance spectroscopy, and cryo-electron microscopy, which provide the foundation for rational drug design.
View Article and Find Full Text PDFAngew Chem Int Ed Engl
August 2025
Department of Chemistry and Division of Advanced Materials Science, Pohang University of Science and Technology (POSTECH), Pohang, 37673, South Korea.
Capture agents that selectively bind to biological targets are indispensable tools in diagnostics, therapeutics, and biomedical research. However, discovering such capture agents, particularly for structurally conserved or challenging targets, remains a challenge. Here, we describe a protein-templated in situ click strategy enabled by a nanoparticle-based DNA-encoded library (nanoDEL) platform.
View Article and Find Full Text PDFOrg Lett
September 2025
State Key Laboratory of Drug Research, Shanghai Institute of MateriaMedica, Chinese Academy of Sciences, Shanghai 201203, P. R. China.
DNA-encoded chemical library (DECL) technology has emerged as a pivotal platform for high-throughput screening in drug discovery. Expanding the chemical space of DECLs requires the development of novel, robust, and DNA-compatible transformations, with atom-economical cyclizations being particularly attractive for generating drug-like scaffolds. The 7,8-dihydropteridinone core represents a pharmacologically important heterocycle whose incorporation into DECLs has been hampered by harsh synthetic conditions.
View Article and Find Full Text PDFJ Med Chem
August 2025
Department of Radiology, Molecular Imaging Innovations Institute (MI3), Weill Cornell Medicine, New York, New York 10065, United States.
Lymphocyte activation gene-3 protein (LAG-3) is an immune checkpoint receptor that promotes T cell exhaustion and immune evasion in cancer. While antibody-based LAG-3 inhibitors have reached the clinic, small molecule modulators remain unexplored. Here, we report compound , the most potent small molecule LAG-3 inhibitor to date.
View Article and Find Full Text PDF